Profund Advisors LLC Sells 9,931 Shares of Biogen Inc. $BIIB

Profund Advisors LLC lowered its holdings in Biogen Inc. (NASDAQ:BIIB) by 41.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 14,200 shares of the biotechnology company’s stock after selling 9,931 shares during the period. Profund Advisors LLC’s holdings in Biogen were worth $2,499,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the company. HighTower Advisors LLC grew its stake in Biogen by 18.2% during the fourth quarter. HighTower Advisors LLC now owns 11,959 shares of the biotechnology company’s stock valued at $2,105,000 after acquiring an additional 1,843 shares in the last quarter. Envestnet Portfolio Solutions Inc. purchased a new stake in shares of Biogen in the 4th quarter valued at $291,000. Mission Wealth Management LP boosted its stake in shares of Biogen by 5.3% in the 4th quarter. Mission Wealth Management LP now owns 1,822 shares of the biotechnology company’s stock valued at $321,000 after purchasing an additional 92 shares in the last quarter. Gabelli Funds LLC boosted its stake in shares of Biogen by 9.2% in the 4th quarter. Gabelli Funds LLC now owns 15,400 shares of the biotechnology company’s stock valued at $2,710,000 after purchasing an additional 1,300 shares in the last quarter. Finally, North Dakota State Investment Board bought a new stake in Biogen during the 4th quarter valued at $1,333,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Biogen Trading Down 0.7%

Biogen stock opened at $190.56 on Wednesday. The stock has a market cap of $28.13 billion, a P/E ratio of 20.45, a PEG ratio of 1.69 and a beta of 0.19. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.06 and a quick ratio of 2.41. Biogen Inc. has a 1 year low of $121.05 and a 1 year high of $205.97. The firm’s 50 day moving average price is $185.40 and its 200-day moving average price is $180.14.

Biogen (NASDAQ:BIIB) last released its quarterly earnings data on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.95 by $0.62. The firm had revenue of $2.48 billion for the quarter, compared to analysts’ expectations of $2.29 billion. Biogen had a net margin of 13.81% and a return on equity of 12.83%. The company’s revenue for the quarter was up 1.9% compared to the same quarter last year. During the same quarter last year, the business posted $3.02 earnings per share. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. On average, equities analysts predict that Biogen Inc. will post 14.18 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently commented on BIIB. JPMorgan Chase & Co. upped their price target on shares of Biogen from $175.00 to $185.00 and gave the company a “neutral” rating in a report on Thursday, April 23rd. TD Cowen increased their price target on shares of Biogen from $175.00 to $215.00 and gave the stock a “buy” rating in a research note on Monday, February 9th. Guggenheim increased their price target on shares of Biogen from $246.00 to $260.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. Evercore began coverage on shares of Biogen in a research report on Friday, May 15th. They set an “outperform” rating on the stock. Finally, Weiss Ratings raised shares of Biogen from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, May 1st. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, thirteen have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $215.62.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.